WaveData Ltd’s Post

Beyond Diabetes Management: Embracing the Power of SGLT2 Inhibitors and GLP1-RA! Did you know these game-changers aren't just for #diabetes? Explore how these drugs are rewriting the narrative for #ASCVD, #CKD, #heartfailure, and weight loss and elevating patient care across the spectrum. To learn how to incorporate these drugs into your practice, visit a pharmacist today! https://lnkd.in/d3gpvbQ #MedicalAdvancements #HeartHealth #BeyondDiabetes #HealthInnovation

Discover the game-changer in diabetes treatment - Glucagon-like peptide-1 (GLP-1) agonists. Why are GLP-1 agonists gaining traction? 1. Effective Blood Sugar Control 2. Weight Management 3. Possible Heart Health Benefits With great power comes the need for safety and expertise. These medications are prevalent in the news media and Pharmacy Benefit Management (PBM) industry, emphasizing the crucial role of pharmacists in ensuring patient safety. Contact us to learn more about how we manage GLP-1s for our members. https://lnkd.in/e_YsE5yt #GLP1Agonists #DiabetesManagement #PatientSafety #PharmacyInnovation #PBMClinicalReview #DiabetesTreatment #BloodSugarControl #PBF #PBM #WeightManagement #HeartHealth #PharmacyBenefitManagement

🎉 Exciting breakthrough in PAH treatment: FDA approves WINREVAIR! 🎉 @Merck has just received the green light from the FDA for WINREVAIR, fantastic news for adults battling Pulmonary Arterial Hypertension (PAH). Let's break it down: 😍 Innovative Therapy: It's the first of its kind, targeting a brand-new pathway in PAH treatment. Just imagine.... opening a new door to better breathing and heart health!!!!! 🏃♂️ Boosted Exercise Capacity: Patients can look forward to not just walking further but feeling better. SIGNIFICANTLY improving exercise ability. 🚀 Rapid Improvements: Alongside standard treatments, it dramatically enhances quality of life, reducing risks of disease progression. 💡 Safety Checks: Regular monitoring ensures that treatment with WINREVAIR stays on the safe side, focusing on hemoglobin and platelet counts. Keep an eye out - it's hitting specialty pharmacies by the end of April! #PAH #WINREVAIR #HealthcareInnovation #FDAApproval #Merck

A 2024 Kaiser Family Foundation survey indicated that 1 in 8 US adults have used GLP-1 medications, primarily for treating chronic conditions like diabetes or heart disease, with nearly 40% using them for weight loss. Meanwhile, a 2023 Morning Consult survey revealed that about 30% of US adults are interested in using GLP-1 drugs for weight loss, although most prefer traditional weight loss methods. The survey found that approximately 80% of respondents believe increasing exercise is an effective and safe way to lose weight, compared to only 33% who consider GLP-1 drugs safe. While 37% of adults see GLP-1 drugs as effective for weight loss, preferences lean toward specific diets, weight loss programs, and surgery over prescription medications. These findings suggest a cautious approach among the public regarding GLP-1 medications, highlighting a preference for established weight loss strategies. #weightloss #exercise #GLP1 Image source: Statista

High-Risk Medications: Why Monitoring is Crucial ? Some medications need careful monitoring to ensure they're safe and effective. Here are a few examples: 💊 Warfarin: Prevents blood clots but increases bleeding risk. Monitor INR levels. 💊 Digoxin: Treats heart conditions but can be toxic. Monitor digoxin levels, renal function, and electrolytes. 💊 Lithium: Stabilizes mood in bipolar disorder but can be toxic. Monitor lithium levels, renal, and thyroid function. 💊 Insulin: Manages diabetes but needs careful dosing. Monitor blood glucose and A1C levels. 💊 Methotrexate: Treats cancer and autoimmune diseases but can be toxic. Monitor CBC, liver, and renal function. Regular monitoring of these medications is essential to stay safe and healthy. Learn more in our latest video! 🎥👇 #pharmacy #healthcare #pharmd #patientcare #healthtips

 #cocreatedwithSanofi #SanofiMedical We all know the importance of finding the right medication for our diabetes management. Did you know that each insulin has its own personality and characteristics? Let’s dive deeper into the key differences between long and longer-acting basal insulin. Uncover fundamental attributes that underpin clinical efficacy, guiding patient choice towards optimal diabetes management. Evaluate duration of action of different basal insulins in relations to PK/PD profiles. Examine glycemic variability across different insulin types. Discover how different insulin types impact hypoglycemia risk and unveil the nuances in their safety profiles. #InsulinDifferentiation #BloodSugarManagement #DiabetesTreatment #InsulinPharmacokinetics #GlycemicVariability #Hypoglycemia #BasalInsulin

#cocreatedwithSanofi #SanofiMedical   We all know the importance of finding the right medication for our diabetes management. Did you know that each insulin has its own personality and characteristics? Let’s dive deeper into the key differences between long and longer-acting basal insulins • Uncover fundamental attributes that underpin clinical efficacy, guiding patient choice towards optimal diabetes management • Evaluate duration of action of different basal insulins in relations to PK/PD profiles • Examine glycemic variability across different insulin types • Discover how different insulin types impact hypoglycemia risk and unveil the nuances in their safety profiles   #InsulinDifferentiation #BloodSugarManagement #DiabetesTreatment #InsulinPharmacokinetics #GlycemicVariability #Hypoglycemia #BasalInsulin

ICYMI: The American College of Physicians released new recommendations for the management of type 2 diabetes with inadequate glycemic control using metformin or other first-line therapies. In a recent #DiabetesDialogue, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES discuss the new recommendations, including the recommended HbA1c targets. Learn more: https://lnkd.in/eqiiAEBf #Type2Diabetes #Diabetes

✨ Breakthrough for Patients with Medication Adherence Challenges ✨ Trelagliptin, a once-weekly DPP-4 inhibitor, is revolutionizing type 2 diabetes management for patients who struggle with medication adherence. Medication adherence is a significant challenge for many patients, leading to suboptimal treatment outcomes and increased healthcare costs. With Trelagliptin's once-weekly dosing, patients can now enjoy improved glucose control and reduced cardiovascular risk with fewer dosing burdens. This breakthrough offers new hope for patients who have struggled with daily or multiple daily doses, enabling them to better manage their condition and improve their quality of life. #MSL #MedicalAffairs #GetzPharma

Have you heard the buzz about GLP-1/GIPs for weight loss and improving blood glucose outcomes? Did you know the GLP-1/GIP medications currently available are only approved for use in people with T2D or obesity? If you are living with T1D and looking to lose weight, you may be eligible for a clinical trial evaluating a new GLP-1/GIP specifically designed to support weight loss and glucose management in those with T1D. Visit the study page to learn more and to answer a few questions to see if you may be eligible. https://hubs.ly/Q02qbsK20 #type1diabetes #t1d #weightloss #GLP1